Compare TRMD & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRMD | LQDA |
|---|---|---|
| Founded | 1889 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | TRMD | LQDA |
|---|---|---|
| Price | $20.50 | $34.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $23.00 | ★ $37.40 |
| AVG Volume (30 Days) | 515.6K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.76 | N/A |
| Revenue | ★ $1,292,300,000.00 | $69,216,000.00 |
| Revenue This Year | N/A | $904.79 |
| Revenue Next Year | N/A | $188.25 |
| P/E Ratio | $7.57 | ★ N/A |
| Revenue Growth | N/A | ★ 343.41 |
| 52 Week Low | $13.60 | $10.37 |
| 52 Week High | $23.67 | $35.54 |
| Indicator | TRMD | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 64.53 |
| Support Level | $20.35 | $32.11 |
| Resistance Level | $20.91 | $35.54 |
| Average True Range (ATR) | 0.38 | 1.55 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 12.74 | 76.90 |
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.